Biocryst Pharmaceuticals Stock Alpha and Beta Analysis
| BCRX Stock | USD 7.50 0.01 0.13% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as BioCryst Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in BioCryst Pharmaceuticals over a specified time horizon. Remember, high BioCryst Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to BioCryst Pharmaceuticals' market risk premium analysis include:
Beta 2.13 | Alpha (0.36) | Risk 3.21 | Sharpe Ratio (0.05) | Expected Return (0.17) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
BioCryst |
BioCryst Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. BioCryst Pharmaceuticals market risk premium is the additional return an investor will receive from holding BioCryst Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in BioCryst Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate BioCryst Pharmaceuticals' performance over market.| α | -0.36 | β | 2.13 |
BioCryst Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of BioCryst Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how BioCryst Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.BioCryst Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how BioCryst Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioCryst Pharmaceuticals shares will generate the highest return on investment. By understating and applying BioCryst Pharmaceuticals stock market price indicators, traders can identify BioCryst Pharmaceuticals position entry and exit signals to maximize returns.
BioCryst Pharmaceuticals Return and Market Media
The median price of BioCryst Pharmaceuticals for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 7.67 with a coefficient of variation of 5.14. The daily time series for the period is distributed with a sample standard deviation of 0.4, arithmetic mean of 7.75, and mean deviation of 0.33. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 100000 shares by Jon Stonehouse of BioCryst Pharmaceuticals at 10.38 subject to Rule 16b-3 | 09/24/2024 |
2 | Inspire Investing LLC Raises Holdings in BioCryst Pharmaceuticals, Inc. | 10/14/2024 |
3 | BioCryst Q3 Earnings Snapshot | 11/04/2024 |
4 | BioCryst Pharmaceuticals Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags | 11/05/2024 |
5 | Earnings call Royalty Pharma reports robust Q3 growth, raises guidance | 11/06/2024 |
6 | Acquisition by Jon Stonehouse of 10000 shares of BioCryst Pharmaceuticals subject to Rule 16b-3 | 11/08/2024 |
7 | BioCryst Pharmaceuticals, Inc. Stock Holdings Increased by Counterweight Ventures LLC - MarketBeat | 11/19/2024 |
8 | BioCryst Pharmaceuticals, Inc. Is Expected To Breakeven In The Near Future | 11/25/2024 |
About BioCryst Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including BioCryst or other stocks. Alpha measures the amount that position in BioCryst Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 12.48 | 15.3 | 7.93 | 6.31 | Receivables Turnover | 5.34 | 5.35 | 5.82 | 2.98 |
BioCryst Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of BioCryst Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioCryst Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of BioCryst Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of BioCryst Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of BioCryst Pharmaceuticals' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with BioCryst Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.